Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And there is so much more news expected this year that "could" result in a significant market cap appreciation. It seems like forever since we have heard from our executives over at IDIX. They must be working pretty darn hard!!! ;)
[OT - SOFO] Figuring that Cisco has acquired up so many players in recent years..... ie; Tandberg, Webex..and now flirting w/Skype, who knows? What has been admitted to by the CEO (Buinevicius) is that they don't see themselves as a standalone company. At some point they expect someone perhaps like CSCO with significant resources to buy them out right. With a market capitalization of only $32 million and annual sales revenue continuing to grow (now greater than $20 million) and margins exceeding 60%.....what does someone like CSCO consider a fair price to acquire the entire company?
That btw is not a question for you....but for the executives at SOFO. jmho
Most of the big volume came in right at the end of the day. I believe you are correct in that some folks have started to cover because they are concerned that September "could" be a big month news wise for IDIX. IMHO :)
Still fun to watch!
How about a volume of 1.412 Million closing up 31 cents? Nice strong push at the end......
OT: SOFO
After a reverse split (1:10) and much time passing by since we last discussed this company, they (Sonic Foundry) finally look to be making some waves. Last quarter they actually made money and look to be continuing to grow their business with both the service and it's hardware. Just wanted to mention this to you and others that might be interested.
agree....very nice to see some buying interest. Still think in many ways we will need a few days with much higher volume (>1 million) for the pps to remain stable above $6
Doesn't get much more anemic than today. I can't remember ever so few shares being traded.
Thank you for sharing your thoughts. Personally I think a buy out would be higher than $12-$15 assuming IDX 320 continues to look promising (especially when combined with IDX 184) in addition to the value that IDX 899 holds for GSK for HIV. JMHO
Best Regards
Price / Share after HCV partnership announcement
...expected later this year
Predictions?
IMHO, all depends on if the deal is for just IDX 184 or both IDX 184 and IDX 320 as you hinted in your question……”HCV partnership announcement”. I think those analysts that are covering IDIX have based for the most part on a partnership for just IDX 184. This as we know is what JP Sommadossi has to some degree has indicated a deal will be agreed to by the end of the calendar year. That being said I am thinking in the $7-$9 range....consistent with many others from all that I have read. If you were to include IDX 320 into the partnership deal and Big Pharma rewards IDIX accordingly.....then I would suggestion $12-$15 as a possible range. Perhaps this is all wishful thinking on my part…..but what IDIX offers is substantial for addressing HCV.
Comments? TIA
First, congrats to you and others on MNTA!!!!
Thank you for answering my inquiries and addressing my poorly asked question apropos HCV and the drugs being developed by IDIX.
It seems to me that IDIX buyout will be much more complicated than I had originally thought as I reviewed your comments-opinion. Time will tell and I am curiously watching how this will all play out.
Cheers!
"I think this thing has a long ways to run."
What is your current definition of a long way to run"? Just curious what your view may be. TIA
Quote
"yet the Street seems to be discounting this part of the IDIX pipeline completely."
Quote from me:
"IDIX—It doesn't seem to me that the IDX899 compound is considered and or appreciated by those covering IDIX when it comes to valuation."
From the Biotech Values Board yesterday morning.... DewDiligence response to what we all have been wondering about.....
I agree and I think there’s an explanation: Until recently, most investors thought GILD owned the HIV market lock, stock, and barrel. A corollary: these investors thought no company had a chance to gain any traction in HIV unless it was working directly with GILD. IDIX’s partner, GSK, was considered a hopeless also-ran in HIV.
These views appear to finally be softening to some degree. Most investors still think non-GILD HIV programs face long odds, but there’s a growing recognition, IMO, that other companies have a shot if they play their cards right. GSK’s program for the integrase inhibitor, ‘572, is case in point (#msg-52482079).
Do you see IDIX being acquired then in the next 5 years assuming their pipeline of HCV drugs continue to demonstrate significant efficacy? TIA.
It doesn't seem to me that the IDX 899 compound is considered and or appreciated by those covering IDIX when it comes to valuation. JMHO
IDIX
Was the Stifel Nicolaus report a re-issue from earlier this year from Thomas Weisel? If not were there any changes or updates you can share? TIA
Regards
LOL.......volume looks anemic. Price moves quick in either direction and probably will until something consequential news wise comes from our friends.......
are there "dog days of summer" when it comes to stocks?
Excellent point!!! Couldn't be a better entry point for those that want to add to their position or jump back in if they took profits earlier.
I have mixed feelings about minding the "gap". I don't understand the technical "need" for this to close....but understand that many that trade stocks do want to see this. Long term though it doesn't really matter does it?????
This looks more like a reiteration of Thomas Weisel coverage from 4/23/10 since Stifel Nicolaus and Thomas Weisel completed their strategic merger, July 1, 2010.
www2.stifel.com/docs/pdf/PressReleases/2010/TWPMerger.pdf
Agree?
OT....DJ Yankees Owner Steinbrenner Died this morning
Hi GG...I sincerely appreciate your technical assessments....they are fun to read and watch IDIX pps with respect to your predictions. Thank you. :)
My read is I don't think there will be much of a sell off if any. Not many of us are expecting news near term any more....it may be that IDIX executives are holding on to the data until the Fall months when they can confirm thier strategic plans for the combination study (IDX 184/320) after getting the required feedback from the FDA. Perhaps as late as November at the AASDL meeting.
I believe IDIX pps will continue to appreciate over these next 3-4 months building to the $8-$9 price range. JMHO
Cheers!
Wells Fargo CC
Thank you sir for sharing your comments. Very much appreciated!
Cheers!
Wells Fargo 23-June 2010
Itching for an update on IDX 184......does anyone think we will hear something new this week?
Hard to fathom from my point of view. I realize the VRTX is much farther ahead in the game then IDIX...but it doesn't explain this much of a market cap difference.
Thanks in advance! Much apprecated. Have a great weekend.
Hi GS! Yes sir....."the" buyout. Just curious, what are your thoughts about the timing of "the buyout" if/when it were to happen? With IDIX's cash on hand, I don't see any immediate pressure/need for JP and the BOD's go this direction any time soon. I think everyone is just anxious to see what comes of the IDX 184 & 320 programs.......
TIA.....Rich
Quote:
"and I do not see JP selling any shares and God knows he owns a fair share"
I think JP will wait until a buyout takes place. I don't see him selling his stash of shares at any price. JMHO
Quote:
What do you think a deal for IDX-184 (assuming it's a "normal" deal for this sort of thing) is worth for the market cap?
Right now as things stand, I believe that it is unlikely that there will be a "deal" for IDX-184 alone. With the emphasis on combining IDX-184 with IDX-320, I feel it is more probable that a much larger deal will be consummated further down the line for the combination 184/320. As far as the "size" of a potential deal and how it will impact the "market cap"...this is totally out of my realm of estimating. So many variables come into play that I would feel silly for even guessing. Previously I have stated that I see IDIX at $9-$12/share over the next 12-18 months. I still stand by that projection today all things considered. IMHO.....IDIX is grossly undervalued.
Buyout
For as much as I would love a buyout sooner than later, I don't see this happening for another 12-18 months, pending IDIX programs advance with very positive results. Just my simple point of view. I've been holding this for well over 3 years. I can wait another 3 for the appropriate valuation for IDIX IP products. Let’s just say I’m sitting on well over 70,000 shares.....so like you...I seriously want to see management bust their tails for all those concerned...including the employees at IDIX. :)
Quote:
Because IDX184 is dosed in this trial for only 14 days, the 28-day data do not give a true RVR rate that one could compare with the RVR rate seen in other HCV trials.
Thank you. Somehow I missed that detail when I looked at IDIX update on the dosing study.
For fun I was watching the ticker tape......at 15.27.34 this afternoon, a trade was executed at $4.00 for 199,900 shares. Was a slow day up until that point. :)
Dear "go seek'.....thank you for this article link. From my perspective, I appreciated how Connell expressed his opinion and built a case for the valuation of FRX going forward. While I don't currently hold a position in this pharma company....It is now on my radar and will start some DD on this issue. Have you yourself considered investing in Forest Labs?
On another note, do you have any idea on timing when we might hear more from IDIX on the 150mg qD IDX-184 results? Last I recall reading, the patients were enrolled. Also, while I am excited about the 14 day results, I am curious as to why IDX didn’t release any 28 day data which I sense would give us a better comparison to other competitors drug candidates for HVC.
t.i.a Rich
ps....DD, please feel free to comment if you have an opinion too about my question apropos IDX184.
that and hiding your Tarot cards when you go to the coffee shop!!!! lmao
Thanks gg. I'm not into charting but enjoy your posts. Once the pps gets above 4.10 (13ema) how "might" things proceed from there? My personal hope is slight upward movement (small changes) over time as new data becomes available. Also with T. Rowe Price significant increase in their equity...I see this as a positive as there are less shares on the floor for traders to flip with. Make any sense?
IDIX
News for 'IDIX' - (*DJ Idenix Pharmaceuticals Raised To Mkt Outperform From Mkt Perform By JMP Securities >IDIX)
Dow Jones Newswires
May 07, 2010 10:02 ET (14:02 GMT)
Copyright (c) 2010 Dow Jones & Company, Inc.- - 10 02 AM EDT 05-07-10
News for 'IDIX' - (*DJ Idenix Pharmaceuticals Raised To Mkt Outperform From Mkt Perform By JMP Securities >IDIX)
Dow Jones Newswires
May 07, 2010 10:02 ET (14:02 GMT)
Copyright (c) 2010 Dow Jones & Company, Inc.- - 10 02 AM EDT 05-07-10
OMG...now that was funny! Thank you!
Good call "gym graity".....only $0.40 from your number. Currently at $3.86. Still think by October 1 that IDIX share price will be significantly higher. Market Cap still seems very low.
Would you happen to know who is the other company that is covering IDIX and still has a target of $3? Perhaps this is a firm that is no longer following IDIX? Thoughts?
TIA
With the recent cash infusion and the current burn rate, IDIX has more than enough time to optimize and negotiate the best possible deal for IDX 184. My best guess is they will have a partnership deal finalized by the start of Q4 2010. JMHO
Not into technical chart reading. Can you explain your observation/assessment it layman's terms? Still buying IDIX. Over the last week I invested much more into this company.....mostly in my IRA. :) Target PPS in 12-18 months I believe is $9-$12. JMHO
Thank you very much. Still hanging in there and considering buying more at this level.